Biologics Breakthrough: Trends in Juvenile Arthritis Over 20 Years
The treatment landscape for juvenile idiopathic arthritis (JIA) has shifted significantly over the past two decades, according to a new study analyzing DMARD (disease-modifying antirheumatic drug) utilization among commercially insured children in the United States from 2001 to 2022.